Simple as 1.2.3!
The Verju is clinically proven to do it all
- Empty out overstuffed fat cell
- Stimulate new collagen
- Tighten up skin
The Verju is clinically proven to do it all
What is cellulite?
Cellulite has many names and is the scourge of many females. It is present in 90% of post-adolescent women and is rarely seen in men. You don't have to be overweight to get it. Cellulite is superficial pockets of trapped fat which cause the skin to have an uneven dimpling or orange peel appearance. It is most commonly located on the thigh, buttocks, and lower abdomen. The cause of cellulite is multi-factorial and is likely due to alterations in the intercellular matrix of the subcutaneous tissue, changes in vascular and lymphatic micro-circulation and influenced by the hormone oestrogen.
How does the Verju get rid of cellulite?
To understand how the Verju can work to smooth away cellulite you need understand how it anatomically is formed. Cellulite is fundamentally the herniation of subcutaneous pockets of fat cells within the fibrous connective tissue which protrude upwards to create the ‘dimpled’ effect in thighs, bottoms and abdomens. Fat cells are grouped together into lobules and held together by vertical aligned connective tissue made up of collagen and elastin called septa. Think of a pocketed sprung mattress. When the fat cells become engorged they expand, stretch and damage the septa pushing it downwards whilst the fat bulges upwards. In men the septa are arranged diagonally so they don’t get the same dimpled effect.
For a successful treatment outcome the damaged septa need to be strengthened and the overstuffed fat cells shrunk. The Verju 532nm wavelength is clinically proven to do both at the same time with no mechanical manipulation, surgical intervention or requirement to radically change diet or run a marathon. The Verju's 532nm wavelength is at the peak absorption point for collagen to trigger neocollangenesis which strengthens and tightens unstable, damaged septae. The reduction in size and volume of adipocytes smoothes out uneven contours. The Verju's photobiological effects on adipocytes facilitates their correct cellular functioning. It is important to treat cellulite fat as a complete endocrine organ to negate the negative etiological factors which contribute towards developing it.
No other body contouring device will actually address the health of fat cells to ensure long term results. They are superficial in effect unlike the Verju!
The Verju has a far reaching health effect on the body unlike other body contouring systems which only treat the fat cells in isolation, but not fat in total as an endocrine organ. To actually destroy and remove fat cells can have a detrimental effect on the endocrine system and allow for fat cells to be formed elsewhere leaving uneven contours!
Cellulite has many names and is the scourge of many females. It is present in 90% of post-adolescent women and is rarely seen in men. You don't have to be overweight to get it. Cellulite is superficial pockets of trapped fat which cause the skin to have an uneven dimpling or orange peel appearance. It is most commonly located on the thigh, buttocks, and lower abdomen. The cause of cellulite is multi-factorial and is likely due to alterations in the intercellular matrix of the subcutaneous tissue, changes in vascular and lymphatic micro-circulation and influenced by the hormone oestrogen.
How does the Verju get rid of cellulite?
To understand how the Verju can work to smooth away cellulite you need understand how it anatomically is formed. Cellulite is fundamentally the herniation of subcutaneous pockets of fat cells within the fibrous connective tissue which protrude upwards to create the ‘dimpled’ effect in thighs, bottoms and abdomens. Fat cells are grouped together into lobules and held together by vertical aligned connective tissue made up of collagen and elastin called septa. Think of a pocketed sprung mattress. When the fat cells become engorged they expand, stretch and damage the septa pushing it downwards whilst the fat bulges upwards. In men the septa are arranged diagonally so they don’t get the same dimpled effect.
For a successful treatment outcome the damaged septa need to be strengthened and the overstuffed fat cells shrunk. The Verju 532nm wavelength is clinically proven to do both at the same time with no mechanical manipulation, surgical intervention or requirement to radically change diet or run a marathon. The Verju's 532nm wavelength is at the peak absorption point for collagen to trigger neocollangenesis which strengthens and tightens unstable, damaged septae. The reduction in size and volume of adipocytes smoothes out uneven contours. The Verju's photobiological effects on adipocytes facilitates their correct cellular functioning. It is important to treat cellulite fat as a complete endocrine organ to negate the negative etiological factors which contribute towards developing it.
No other body contouring device will actually address the health of fat cells to ensure long term results. They are superficial in effect unlike the Verju!
The Verju has a far reaching health effect on the body unlike other body contouring systems which only treat the fat cells in isolation, but not fat in total as an endocrine organ. To actually destroy and remove fat cells can have a detrimental effect on the endocrine system and allow for fat cells to be formed elsewhere leaving uneven contours!
Below are some examples of the clinical data to demonstrate the effectiveness of Low Level Laser therapy in body contouring, including the double -blind, placebo-controlled randomised trial that was submitted for FDA clearance
|
Appearance of Cellulite - Verju published paper
The Verjú is a multi-faceted approach to treat the appearance of Cellulite, and is the only device to be backed by a level (1), placebo controlled study to prove its efficacy. The Verjú is a transdermal laser that penetrates the skin to treat hypertrophic adipocytes while increasing dermal collagen and stabilizing the fibrotic septae collagen. A Double-Blind, Placebo-Controlled Randomized Trial Evaluating the Ability of Low-Level Laser Therapy to Improve the Appearance of Cellulite Robert F. Jackson, MD, Gregory C. Roche, DO, and Steven Shanks 
|
Erchonia Clinical Research
Although previous studies had answered important questions, one new question surfaced: Can laser therapy serve as a standalone non-invasive body contouring device? In 2008, Erchonia started to answer this question. Data from an initial pilot study produced meaningful circumferential losses from the waist, hips, and thighs in just two weeks. These data were published in Lasers in Surgery and Medicine in 2008. Erchonia recognized the potential of this application and scheduled an Investigational Device Exemption meeting with the FDA to design an appropriate clinical study. Erchonia, using the comments provided by the FDA, designed a placebo-controlled, randomized, double-blind clinical study. Additionally, subjects were required to keep a daily dietary journal, recording any departure from their normal lifestyle. If a change was documented, the subject would have been excused from the study. No diet, exercise, or supplemental program was used any time during the study. After a two-week treatment administration period, a majority of subjects exceeded the FDA’s success criterion of at least a 3.0 inch loss from the waist, hips, and thighs. The data was published in 2009 in Lasers in Surgery and Medicine. Low-Level Laser Therapy as a Non-Invasive Approach for Body Contouring: A Randomized, Controlled Study Lasers in Surgery Medicine 41: 799-809 (2009) |
Fat Liquification -Depth Penetration
Between 2001 and 2004, numerous research projects were initiated to answer basic questions regarding laser physics: How far can laser penetrate abdominal subcutaneous fat? Can it affect both superficial and deep subcutaneous fat? Could laser serve as a viable tool as an adjunct to liposuction or as a standalone contouring technology? In 2001, Magnetic Resonance Imaging (MRI) showed laser therapy emulsified fat as deep as 5.0 cm, affecting both superficial and deep subcutaneous fat. In 2004, a randomized, controlled clinical trial revealed test subjects undergoing laser treatment presented with softer fat. This study led to the first and only 510(k) market clearance granted to a laser device (The Erchonia EML) as an adjunct treatment to liposuction. Fat Liquefaction: Effect of Low-Level Laser Energy on Adipose Tissue Rodrigo Neira, M.D., Jose Arroyave, B.S.C.E., T.E.M., S.E.M., Hugo Ramierez, M.V., Clara Lucia Ortiz, M.D., Efrain Solarte, Dr. rer. nat. Federico Sequeda, Ph.D., and Maria Isabel Gutierrez, M.D., M.Se., Ph.D. |
|
|
|
